Lifescience investor focused on non-consensus long-short investment ideas. I focus on small to mid-cap biotechnology companies that are public on the US and EU markets. I like to delve into clinical catalysts or play earnings on new drug launches. I do not provide personal investment advice. All content that I provide, including but not limited to opinions, analyses, commentaries, forecasts, stock picks, and investment strategies, is for informational and educational purposes only and should not be interpre ...

Clinical Development - The company is advancing PALI-2108, a once-daily oral PDE4 inhibitor prodrug, towards a Phase 2 clinical study in ulcerative colitis (UC) to evaluate clinical remission response and pharmacodynamic biomarkers over 12 weeks [24]. - The Phase 1 clinical study of PALI-2108 has completed dosing of 89 subjects, with positive results reported for safety, tolerability, and pharmacokinetics [39]. - The exploratory Phase 1b cohort in fibrotic strictures of Crohn's disease (FSCD) is expected to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics over a 14-day treatment period [40]. - The company plans to submit Investigational New Drug Applications (IND) to the FDA for Phase 2 studies in UC and CD in 2026 [42]. - The company has commenced a Phase 1 clinical trial for PALI-2108 in Canada, with positive results reported from various cohorts [196]. - The lead clinical product candidate, PALI-2108, may face regulatory approval challenges due to potential undesirable side effects [211]. - Clinical trials could be suspended or terminated if unacceptable severity and prevalence of side effects are revealed, adversely affecting business and financial condition [212]. - Regulatory approval for PALI-2108 requires significant development, clinical testing, and substantial financial investment, with no assurance of success [214]. Market Overview - The market for ulcerative colitis (UC) treatments was valued at approximately $7.3 billion in 2021 and is expected to grow to over $9.5 billion by 2031, reflecting a compound annual growth rate (CAGR) of approximately 2.78% [43]. - Diagnosed incident cases of UC in the eight major markets (8MM) are projected to increase from 160,122 cases in 2021 to 168,467 cases by 2031, with an annual growth rate (AGR) of 0.52% [43]. - The global market for Crohn's disease (CD) treatments was valued at $13.9 billion in 2022 and is projected to grow to approximately $25.5 billion by 2032, with a CAGR of approximately 6% [45]. - Diagnosed incident cases of CD in the 8MM are expected to increase from 118,885 cases in 2022 to 122,175 cases by 2032, reflecting an AGR of 0.28% [44]. Regulatory Environment - The FDA requires extensive monitoring and auditing of all clinical activities and data during all phases of clinical development [87]. - Phase 3 clinical trials, referred to as pivotal studies, typically require two adequate and well-controlled trials for NDA approval, although one may suffice with supporting evidence [88]. - The FDA reviews an NDA within 60 days to determine if it is substantially complete before accepting it for filing [100]. - The FDA may impose restrictions on product distribution and require post-marketing clinical trials for approved products [105]. - The FDA has performance goals under the PDUFA, aiming to review standard NDAs in ten months and priority NDAs in six months [106]. - The FDA has various expedited programs to facilitate the development and review of drugs for serious or life-threatening conditions [107]. - IND safety reports must be submitted within seven calendar days for unexpected fatal or life-threatening adverse reactions [89]. - Compliance with cGMP regulations is mandatory for manufacturers to ensure consistent production of pharmaceutical products [94]. - The FDA may refuse to file any NDA deemed incomplete or not properly reviewable at the time of submission [100]. - The FDA may require a REMS to ensure the safe use of a product candidate if deemed necessary [102]. - The Fast Track program allows expedited review for new drugs and biologics intended to treat serious conditions, with increased FDA interactions during development [108]. - Priority review designation can reduce FDA review time to six months from the standard ten months for drugs showing significant safety or effectiveness improvements [110]. - Accelerated approval may be granted for drugs that provide meaningful advantages over existing therapies, based on surrogate endpoints or earlier clinical endpoints [111]. - Breakthrough therapy designation offers intensive guidance and expedited development for drugs showing substantial improvement over existing therapies [112]. - The FDA's Commissioner's National Priority Voucher pilot program aims to accelerate reviews for products addressing key national health priorities, with targeted review completion within 1-2 months [113]. - Post-approval requirements include annual user fees and compliance with cGMP regulations, emphasizing quality control and safety [116]. Intellectual Property - The company has exclusive rights to one pending patent application in the U.S. and six pending applications internationally related to PALI-2108 [73]. - A Notice of Allowance for the patent covering PALI-2108 was issued by the China National Intellectual Property Administration in July 2025 [73]. - The expected expiration date of the patent related to LB1148 is 2031, excluding any adjustments or extensions [77]. - The Hatch-Waxman Amendments allow for patent term extensions of up to five years for drugs lost during development and FDA review, with a maximum total patent life of 14 years [128]. - New Chemical Entity (NCE) exclusivity provides five years of non-patent marketing exclusivity for the first approved drug containing an NCE [134]. - A drug may obtain a three-year exclusivity for a new indication if new clinical trials were essential for approval [135]. - Orphan drug exclusivity grants seven years of market protection for drugs approved for rare diseases affecting fewer than 200,000 individuals in the U.S. [138]. - Pediatric exclusivity can extend marketing protection by six months if pediatric research is conducted as requested by the FDA [139]. Financial and Operational Considerations - The company has not yet established a commercial organization or distribution capabilities for potential product candidates [55]. - The company relies on third parties for clinical supply and manufacturing of its product candidates, including PALI-2108 [56][60]. - LBS engages a network of third-party CDMOs and CMOs to ensure quality and compliance in drug development and manufacturing [58]. - The company expects to have sufficient capital to fund operations through major clinical development milestones, including a Phase 2 primary efficacy readout of PALI-2108 for UC expected in the second half of 2027 [207]. - The company faces challenges in patient enrollment for clinical trials, which could delay or prevent trial completion [205]. - The company must navigate evolving data privacy laws, such as the California Consumer Privacy Act (CCPA), which may increase compliance costs and potential liabilities [164]. - The company faces risks related to data security and privacy regulations, which are rapidly changing and could impose significant operational costs [161]. - The implementation of cost containment measures may adversely affect the company's ability to generate revenue and achieve profitability [154]. Competitive Landscape - LBS faces competition from large pharmaceutical companies and emerging biotech firms in the IBD treatment space, impacting market share [65][66]. - The company’s product candidates, if approved, would compete with established therapies such as TNF antibodies and JAK inhibitors for moderate-to-severe IBD [69][70]. Legislative and Policy Changes - The U.S. healthcare system is undergoing significant reforms aimed at controlling costs and improving access, which may impact the profitability of pharmaceutical products [146]. - The Affordable Care Act (ACA) includes provisions that affect pharmaceutical manufacturers, such as Medicaid rebates and annual fees on branded drugs, which could influence revenue streams [147]. - The Inflation Reduction Act (IRA) mandates price negotiations for high Medicare spend drugs starting in 2026, potentially affecting pricing strategies and revenue [149]. - Legislative changes, including the establishment of the "Department of Government Efficiency," may lead to operational disruptions and delays in FDA approvals, impacting product development timelines [150]. - The current administration's executive orders focus on lowering drug prices and increasing competition, which may create additional pricing pressures for pharmaceutical companies [151]. - State-level regulations are increasingly controlling drug pricing and reimbursement, which could lead to reduced revenue from both government and private payors [154]. - Compliance with government pricing programs, such as the Medicaid Drug Rebate program and the 340B Drug Pricing program, imposes financial obligations on manufacturers that could affect profitability [155][156]. Subsidiaries and Agreements - The company has two wholly owned subsidiaries, with one, Suzhou Neuralstem Biopharmaceutical Co., Ltd., currently in the process of dissolution [182]. - The company issued contingent value rights (CVRs) entitling holders to 80% of net proceeds from the sale or licensing of legacy technology, with no payments made to CVR holders to date [183]. - The company has an exclusive license for NSI-189 assets, with a purchase option that was early exercised by Alto Neuroscience [184]. - Alto is required to pay up to $4.5 million upon achieving certain development and regulatory approval milestones for ALTO-100, with a maximum aggregate payment of $5.0 million under the ATA [186]. - A milestone payment of $1.5 million will be due from Alto upon the enrollment of a patient in a Phase 3 clinical trial of ALTO-100 [187]. - The University of Michigan will bear 100% of the costs for patent filing and maintenance related to NSI-532.IGF-1, with the company receiving 50% of net revenues from licensing [188].

Core Insights - The article discusses the best growth stocks to buy currently, highlighting specific companies and their recent developments that may impact investor sentiment. Group 1: Market Analysis - Chief Investment Strategist at Hightower, Stephanie Link, suggests that investors should capitalize on current market dislocations, especially given the missed 34% rally for those who sold during Liberation Day [2] - John Mowrey from NFJ Investment Group emphasizes potential gains in smaller-cap stocks affected by interest rate concerns, distinguishing between shock inflation from oil price spikes and hot inflation from economic overheating [3] - Mowrey notes that technology stocks are becoming attractive as their multiples compress into the low 20s, despite a compound annual growth rate (CAGR) exceeding 30% [3] Group 2: Methodology for Stock Selection - The methodology used to identify stocks includes screening for those with a track record of delivering earnings growth, specifically those that have grown their earnings per share (EPS) by at least 20% over the past three years [5] - The final selection is limited to companies that have reported noteworthy developments likely to impact investor sentiment and are popular among analysts and elite hedge funds [5][6] Group 3: Company Highlights - **Palisade Bio Inc. (NASDAQ:PALI)**: Recently presented data from its Phase 1b study of PALI-2108, showing a 100% clinical response rate and a 40% clinical remission rate in patients with moderate-to-severe ulcerative colitis [7][8] - The drug demonstrated localized target engagement and clinical response within 7 days, with a favorable safety profile across 89 subjects [8][10] - **Blend Labs Inc. (NYSE:BLND)**: Launched Blend Autopilot, an AI agent that automates loan reviews in as little as 15 seconds, addressing delays in the traditional mortgage cycle [12][14] - The technology aims to enhance efficiency by automating document parsing and compliance checks while leaving final credit determinations to human underwriters [13][14]

Summary of Palisade Bio FY Conference Call Company Overview - **Company**: Palisade Bio (NasdaqCM:PALI) - **Industry**: Biotechnology, specifically focusing on oral therapeutics in the Inflammatory and Immune (I&I) space - **Lead Drug**: PALI-2108, a PDE4 inhibitor developed for treating inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis [2][3] Core Points and Arguments - **Drug Development Background**: - PALI-2108 was originally developed by Merck and later reformulated as a prodrug by Giiant Pharma [2] - The prodrug formulation is crucial as it mitigates severe adverse events associated with traditional PDE4 inhibitors, such as secretory diarrhea and CNS events [3][4] - **Clinical Development Status**: - Completed preclinical development and initiated clinical trials, treating 84 healthy volunteers and 5 ulcerative colitis patients [4][5] - Currently conducting a small cohort study in fibrostenotic Crohn's disease, with results expected by the end of the month [5] - Plans to file an IND for a definitive study in ulcerative colitis involving 196 patients by May, with patient treatment starting in early Q3 2026 and data readout by the end of 2027 [5][13] - **Market Potential**: - Crohn's disease and ulcerative colitis are multi-billion dollar markets, with fibrostenotic Crohn's disease being a significant unmet need as there are currently no approved therapies [14] - The company aims to differentiate itself with a dual-acting anti-inflammatory and anti-fibrotic drug, which is unique in the market [11][19] - **Competitive Landscape**: - Competitors include Agomab, which recently IPO'd at over $750 million, and other PDE4 inhibitors like AstraZeneca's roflumilast and Amgen's Otezla [12][14] - The company has developed a precision medicine test to identify potential responders to PALI-2108 [12] - **Efficacy and Safety Data**: - Early data from a phase 1B study showed promising results, including a 63% improvement in the modified Mayo score and significant reductions in inflammatory markers after just one week of treatment [24][42] - The drug demonstrated good safety and tolerability, with no serious adverse events reported even at high doses [44][45] Additional Important Content - **Financial Position**: - Completed a financing round in October 2025, providing sufficient funds to support definitive studies in both ulcerative colitis and fibrostenotic Crohn's disease, with a runway extending into 2029 [30][31] - **Team and Expertise**: - The company has built a strong team with experience from major pharmaceutical companies, enhancing its capability to execute its development plans [32] - **Regulatory Considerations**: - The company is evaluating whether to pursue a broader indication for Crohn's disease or focus specifically on fibrosing Crohn's, depending on the data from ongoing studies [33][34] - **Market Positioning**: - The company aims to position PALI-2108 as a faster-acting oral option in a market currently dominated by injectable therapies with lower remission rates [40][41] - **Long-term Durability of Response**: - The company is confident in the long-term efficacy of PALI-2108 based on historical data from other PDE4 inhibitors and ongoing studies [42][43] This summary encapsulates the key points discussed during the Palisade Bio FY Conference Call, highlighting the company's strategic direction, clinical development progress, market potential, and competitive landscape.

Summary of Palisade Bio FY Conference Call Company Overview - **Company**: Palisade Bio (NasdaqCM:PALI) - **Industry**: Biotechnology, specifically focusing on oral therapeutics in the Inflammatory & Immune (I&I) space - **Lead Drug**: PALI-2108, a PDE4 inhibitor developed for treating inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis [2][3] Core Points and Arguments Drug Development and Mechanism - PALI-2108 is a prodrug formulation that releases its active ingredient in the lower gastrointestinal (GI) tract, avoiding adverse events associated with traditional PDE4 inhibitors, such as secretory diarrhea and CNS events like headache and nausea [3][4] - The drug has shown efficacy in treating IBD diseases, with a focus on reducing adverse events by localizing the drug's action [3][4] Clinical Trials and Milestones - Completed preclinical development and initiated clinical trials, treating 84 healthy volunteers and 5 ulcerative colitis patients in a Phase 1b cohort [4][5] - A small cohort study in fibrostenotic Crohn's disease is expected to read out by the end of March 2026 [5] - Plans to file an Investigational New Drug (IND) application for ulcerative colitis in May 2026, with patient treatment starting in early Q3 2026 and data readout by the end of 2027 [5][13] Market Potential - Crohn's disease and ulcerative colitis are identified as multi-billion dollar markets, with fibrostenotic Crohn's disease being a significant unmet need as there are currently no approved therapies [14] - The company aims to differentiate itself by being the first dual-acting anti-inflammatory and anti-fibrotic drug in development for fibrostenotic Crohn's disease [11][14] Competitive Landscape - Competitors include Agomab, which recently IPO'd at over $750 million, and other PDE4 inhibitors like AstraZeneca's roflumilast and Amgen's Otezla [12][14] - The company is developing a precision medicine test to identify potential responders to PALI-2108, enhancing its competitive edge [12][19] Financial Overview - Completed a transformational financing in October 2025, providing sufficient funds to support definitive studies in both ulcerative colitis and fibrostenotic Crohn's disease, with a runway extending into 2029 [28][29] - The company maintains a clean capital structure with 206 million shares fully diluted [28][29] Key Insights and Considerations - The drug's design aims to minimize common PDE4-related adverse events, which could enhance its market acceptance [43][44] - The company emphasizes its capital efficiency and execution capabilities, which may be underappreciated in the market [47][48] - There is ongoing evaluation regarding whether to pursue a broader indication for Crohn's disease or focus specifically on fibrosing Crohn's, pending data from the Phase 1b cohort [31][33] Conclusion Palisade Bio is positioned in a promising niche within the biotechnology sector, focusing on innovative oral therapeutics for IBD. The company's strategic development of PALI-2108, along with its financial backing and market potential, presents a compelling case for investors looking for opportunities in the healthcare space.

Core Viewpoint - Palisade Bio, Inc. is advancing its clinical-stage biopharmaceutical development of a next-generation oral PDE4 inhibitor prodrug, PALI-2108, aimed at treating inflammatory and fibrotic diseases, with upcoming investor presentations scheduled for March 2026 [1][2][3]. Group 1: Company Overview - Palisade Bio is focused on developing oral PDE4 inhibitor prodrugs that enhance pharmacology, tolerability, and convenience for patients suffering from inflammatory and fibrotic diseases [3]. - The company's lead program, PALI-2108, is designed for targeted delivery in the ileum and colon, achieving a 100% clinical response in a recent Phase 1b trial for ulcerative colitis (UC) without serious adverse events [4]. Group 2: Clinical Development - Palisade Bio is progressing towards a Phase 2 clinical study in UC, which will evaluate clinical remission, response, and pharmacodynamic biomarkers over a 12-week period, including an extension phase for maintenance of remission [5]. - The company is also conducting early studies in fibrostenotic Crohn's disease to further assess the safety and therapeutic potential of PALI-2108 across various inflammatory bowel disease indications [5]. Group 3: Investor Engagement - Palisade Bio will participate in the TD Cowen 46th Annual Health Care Conference on March 2, 2026, and the Leerink Partners 2026 Global Healthcare Conference from March 8-11, 2026, providing opportunities for investors to engage with management [1][2].

Summary of Palisade Bio FY Conference Call Company Overview - **Company**: Palisade Bio (NasdaqCM:PALI) - **History**: Established approximately 16 years ago, with a significant transformation occurring in summer 2023 after a phase 2 study yielded disappointing results. The company pivoted to focus on a PDE4 inhibitor acquired from Giiant Pharma, which was originally developed in Merck labs in Montreal [4][5]. Core Product and Mechanism - **Product**: PALI-2108, a prodrug PDE4 inhibitor designed to mitigate common adverse effects associated with traditional PDE4 inhibitors, such as diarrhea, headache, and nausea [7][9]. - **Mechanism**: The prodrug formulation allows for gut-restricted action, releasing the active ingredient in the distal gut, thus avoiding upper gastrointestinal issues. It has a long half-life and is administered once daily, which is unique among PDE4 inhibitors [10][11][12]. Clinical Development - **Phase 1A and 1B Studies**: Completed with promising results, including a 63% improvement in modified Mayo score in a small open-label study of 5 ulcerative colitis (UC) patients [18]. - **Phase II Plans**: Enrollment for the Phase II UC study is expected to start in Q3 2026, with top-line results anticipated by the end of 2027. The study aims to include 50-70% bio-experienced patients [23][39]. Market Opportunity - **Fibrostenosing Crohn's Disease (FSCD)**: Identified as a significant unmet need, with 75% of Crohn's patients requiring surgery for strictures. There are approximately 200,000 symptomatic patients in the U.S. alone [27]. - **Potential for Broader Applications**: The drug's mechanism may also be applicable to other inflammatory conditions, including COPD and IPF, due to its improved pharmacology and tolerability [43]. Financial Position - **Funding**: The company raised $138 million in a re-IPO, providing sufficient runway to conduct definitive studies in UC and Crohn's, with cash expected to last into 2029 [40]. Strategic Considerations - **Corporate Development**: The company is in early discussions with large pharmaceutical firms to raise awareness of its developments, preparing for potential partnerships as data becomes available [45]. Key Takeaways - **Innovative Approach**: PALI-2108's prodrug formulation represents a significant advancement in the treatment of inflammatory bowel diseases, aiming to improve patient tolerability and outcomes. - **Strong Pipeline**: The company is strategically positioned to address significant unmet needs in both UC and Crohn's disease, with plans for future studies and potential expansion into other therapeutic areas. - **Robust Financial Backing**: The recent funding provides a solid foundation for ongoing clinical trials and development efforts, enhancing the company's prospects for success in the competitive biotech landscape.

Core Insights - Palisade Bio, Inc. presented new translational data for PALI-2108, a targeted oral PDE4 inhibitor prodrug, at the 21st Congress of the European Crohn's and Colitis Organization (ECCO) in Stockholm, demonstrating localized target engagement and early clinical response within seven days [1][2][10] Group 1: Clinical Findings - In a Phase 1b trial involving patients with moderate-to-severe ulcerative colitis (UC), PALI-2108 achieved a 100% clinical response rate, with 40% of patients reaching clinical remission as measured by the modified Mayo Score [5][9] - The treatment resulted in significant downregulation of inflammatory and fibrosis-associated gene expression programs, including suppression of TNF-α, JAK–STAT, NF-κB, MAPK, and TGF-β pathways [5][6] - Histologic improvements were observed alongside reductions in fecal calprotectin and high-sensitivity C-reactive protein (hsCRP) levels, indicating a decrease in inflammation [5][6] Group 2: Mechanism of Action - PALI-2108 is designed for localized delivery to the terminal ileum and colon, where it is bioactivated by bacterial enzymes, allowing for targeted PDE4 inhibition at sites of inflammation while minimizing systemic exposure [7][9] - The prodrug's pharmacological activity was confirmed through RNA sequencing and pathway analyses, which showed localized suppression of inflammatory signaling networks in colonic tissue, with peripheral immune profiles remaining largely unchanged [4][6] Group 3: Safety and Tolerability - The safety profile of PALI-2108 was encouraging, with no serious adverse events reported among the 89 subjects in the study, supporting its potential as a differentiated treatment option for inflammatory bowel diseases [1][9] - The localized pharmacology of PALI-2108 aims to improve tolerability by reducing common side effects associated with systemic PDE4 inhibitors, such as diarrhea, nausea, and headache [7][8] Group 4: Future Development - Palisade Bio is advancing PALI-2108 into a Phase 2 clinical study to evaluate clinical remission, response, and pharmacodynamic biomarkers over a 12-week period, with plans for an extension phase to assess maintenance of remission [10]

Core Insights - Palisade Bio, Inc. has appointed Dr. Bram Verstockt to its Clinical Advisory Board to enhance its Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease [1][2] - The company plans to submit an Investigational New Drug (IND) application for PALI-2108 in ulcerative colitis in the first half of 2026 [1][8] Company Overview - Palisade Bio is a clinical-stage biopharmaceutical company focused on developing next-generation oral PDE4 inhibitor prodrugs aimed at chronic inflammatory and fibrotic diseases [11] - The lead program, PALI-2108, is designed for targeted delivery to the terminal ileum and colon, utilizing local bacterial bioactivation to convert the prodrug into an active PDE4 inhibitor [9][10] Clinical Development - PALI-2108 has shown a 100% clinical response in a Phase 1b trial for ulcerative colitis, with no serious adverse events reported [12] - The upcoming Phase 2 study will evaluate clinical remission, response, and pharmacodynamic biomarkers over a 12-week period, with an extension phase for maintenance of remission [13] Expert Contribution - Dr. Verstockt's expertise in inflammatory bowel disease and precision medicine will be crucial for optimizing patient selection, endpoint strategy, and disease monitoring in the Phase 2 studies [3][8] - His background in advanced imaging, biomarker integration, and multi-omics research will support the design of studies aimed at demonstrating durable efficacy and disease modification [3][6]

Company Overview - Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation, once-daily oral PDE4 inhibitor prodrugs aimed at targeted delivery to the terminal ileum and colon [2][6] - The company's lead program, PALI-2108, is designed to improve pharmacology, tolerability, and convenience for patients with inflammatory and fibrotic diseases [6][7] Product Details - PALI-2108 is a once-daily oral prodrug that is pharmacologically inactive until it reaches the lower intestine, where it is activated by bacterial enzymes at sites of inflammation and fibrosis [5][7] - In a recent Phase 1b trial, PALI-2108 achieved a 100% clinical response in the ulcerative colitis (UC) cohort, with no serious adverse events reported [7] - The company is advancing towards a Phase 2 clinical study in UC, which will evaluate clinical remission, response, and pharmacodynamic biomarkers over 12 weeks [8] Upcoming Events - JD Finley, CEO, and Dr. Mitchell Jones, President and CMO, will participate in a virtual fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium on February 12, 2026 [2][3] - A live webcast of the presentation will be available on the company's website, with a replay accessible for a limited time [4]